Bank of New York Mellon
VRDN icon

Bank of New York Mellon’s Viridian Therapeutics VRDN Stock Holding History

Bank of New York Mellon’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.92M Buy
268,060
+51,535
+24% +$830K ﹤0.01% 2449
2026
Q1 		$4.24M Buy
216,525
+659
+0.3% +$19.6K ﹤0.01% 2413
2025
Q4 		$6.72M Buy
215,866
+18,696
+9% +$513K ﹤0.01% 2153
2025
Q3 		$4.25M Buy
197,170
+4,646
+2% +$83.8K ﹤0.01% 2416
2025
Q2 		$2.69M Sell
192,524
-5,653
-3% -$76.7K ﹤0.01% 2604
2025
Q1 		$2.67M Buy
198,177
+1,655
+0.8% +$28.2K ﹤0.01% 2547
2024
Q4 		$3.77M Buy
196,522
+25,692
+15% +$559K ﹤0.01% 2439
2024
Q3 		$3.89M Sell
170,830
-37,846
-18% -$619K ﹤0.01% 2417
2024
Q2 		$2.71M Buy
208,676
+56,814
+37% +$786K ﹤0.01% 2628
2024
Q1 		$2.66M Buy
151,862
+2,051
+1% +$39.8K ﹤0.01% 2623
2023
Q4 		$3.26M Buy
149,811
+11,634
+8% +$184K ﹤0.01% 2583
2023
Q3 		$2.12M Sell
138,177
-3,875
-3% -$73.9K ﹤0.01% 2774
2023
Q2 		$3.38M Buy
142,052
+2,417
+2% +$62K ﹤0.01% 2545
2023
Q1 		$3.55M Sell
139,635
-12,918
-8% -$414K ﹤0.01% 2486
2022
Q4 		$4.46M Buy
152,553
+62,290
+69% +$1.44M ﹤0.01% 2403
2022
Q3 		$1.85M Buy
90,263
+20,983
+30% +$377K ﹤0.01% 2908
2022
Q2 		$802K Buy
+69,280
New +$931K ﹤0.01% 3318
2019
Q4 		– Sell
-1,349
Closed -$15K – 4236
2019
Q3 		$15K Sell
1,349
-752
-36% -$16.6K ﹤0.01% 4197
2019
Q2 		$65K Sell
2,101
-4,805
-70% -$193K ﹤0.01% 4096
2019
Q1 		$289K Buy
6,906
+250
+4% +$11.3K ﹤0.01% 3754
2018
Q4 		$302K Buy
6,656
+2,473
+59% +$143K ﹤0.01% 3707
2018
Q3 		$350K Buy
4,183
+189
+5% +$17.8K ﹤0.01% 3780
2018
Q2 		$384K Buy
3,994
+1,638
+70% +$173K ﹤0.01% 3749
2018
Q1 		$248K Sell
2,356
-696
-23% -$75.6K ﹤0.01% 3857
2017
Q4 		$478K Buy
3,052
+1,225
+67% +$156K ﹤0.01% 3635
2017
Q3 		$250K Sell
1,827
-5
-0.3% -$841 ﹤0.01% 3817
2017
Q2 		$355K Buy
+1,832
New +$309K ﹤0.01% 3747

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Bank of New York Mellon's VRDN Position: Q2 2026 in Review

Bank of New York Mellon increased its Viridian Therapeutics (VRDN) stake by 24% in Q2 2026, buying an estimated $830K and bringing the position to 268,060 shares worth $4.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2449.

Bank of New York Mellon first reported a position in VRDN in Q2 2017 and has held it in 27 quarters since. The position peaked at $6.72M in Q4 2025. 92 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Bank of New York Mellon held 268,060 shares of Viridian Therapeutics worth $4.92M as of Q2 2026.
  • Bank of New York Mellon bought 51,535 Viridian Therapeutics shares in Q2 2026, an estimated $830K.
  • Viridian Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2449 holding.
  • Bank of New York Mellon first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 27 quarters since.
  • Bank of New York Mellon's Viridian Therapeutics position peaked at $6.72M in Q4 2025.
  • 92 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.